Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.26 Million of Units
MINNEAPOLIS , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to $1.26
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
MINNEAPOLIS , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be no
View HTML
Toggle Summary Precision Therapeutics Inc. is Excited to Announce a Special Meeting of Stockholders and Commencement of Registered Exchange Offer
MINNEAPOLIS , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision”) today announced the effectiveness of its Form S-4 registration statement, the establishment of the date of its special meeting of stockholders in connection with the proposed business
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria
MINNEAPOLIS , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its Skyline Medical division, producer of the FDA-approved and CE-marked  STREAMWAY ® System  for automated, direct-to-drain medical fluid disposal, has received
View HTML
Toggle Summary Precision Therapeutics’ TumorGenesis Division Isolates Discovery Biomarkers for Thyroid Cancer Cell Types, Initiating Its Proprietary Process for New Drug Development Via Patient-Derived Tumor Models
MINNEAPOLIS , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the discovery biomarkers.  The company will utilize this discovery to
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Widens Global Reach Through New Taiwanese Distribution Agreement with Winner Scientific
Company Further Expands Global Outreach Through Exhibition at Arab Health Show in Dubai MINNEAPOLIS , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and
View HTML
Toggle Summary Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz
MINNEAPOLIS , Jan. 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its chief executive officer and director, Carl Schwartz , has made an additional investment of $1,000,000 in the Company, effective January 8, 2019 .
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Significantly Expands Footprint in New England With Sale of Six STREAMWAY Systems to Yale University Ambulatory Outpatient Surgical Center
Large Sale to Prestigious Health System Further Validates STREAMLINE Utility MINNEAPOLIS , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked 
View HTML
Toggle Summary Precision Therapeutics Reports Third Quarter 2018 Financial Results
MINNEAPOLIS , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three and nine months ended
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on November 14, 2018
MINNEAPOLIS , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the
View HTML